Literature DB >> 27165811

Unemployment and initiation of psychotropic medication: a case-crossover study of 2 348 552 Norwegian employees.

Silje L Kaspersen1, Kristine Pape2, Solveig O Ose3, David Gunnell4, Johan Håkon Bjørngaard5.   

Abstract

OBJECTIVES: The study investigated initiation of psychotropic medication in relation to unemployment in the months before, during and after job loss, to detect the period of greatest risk.
METHODS: The Norwegian working population in 2004 (N=2 348 552) was observed from 2005 to 2010 through administrative registries linked to the Norwegian Prescription Database. A case-crossover design was used to analyse within-person relative risk of incident purchases of prescribed psychotropic drugs in relation to timing of unemployment. Control periods were defined 12, 24 and 36 months before the drug purchase. Supplementary analyses were performed on medication for cardiovascular disease, diabetes, obesity, thyroid disorder, pain and musculoskeletal conditions.
RESULTS: Purchases of all psychotropic drugs increased 1-3 months before job loss. Antidepressants had the highest estimate in the month before job loss (OR 2.68, 95% CIs 2.39 to 3.01), followed by hypnotics/sedatives (OR 2.21, 95% CI 1.97 to 2.48), anxiolytics (OR 2.18, 95% CI 1.91 to 2.48) and antipsychotics (OR 2.09, 95% CI 1.76 to 2.48). Rises were greatest in men. Risk of starting psychotropic medication remained raised during a spell of unemployment, but returned to close-to-baseline levels following re-employment. Drugs used to treat somatic and pain conditions showed similar trends but with weaker associations.
CONCLUSIONS: Concerns about impending unemployment may influence mental health several months prior to job loss, especially around the time of notification. The clinical implications of this might be a strengthening of preventive health initiatives early in the unemployment process. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Anxiety; Depression; Job insecurity; Job loss

Mesh:

Substances:

Year:  2016        PMID: 27165811     DOI: 10.1136/oemed-2016-103578

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  6 in total

1.  Current Unemployment, Unemployment History, and Mental Health: A Fixed-Effects Model Approach.

Authors:  Liina Junna; Heta Moustgaard; Pekka Martikainen
Journal:  Am J Epidemiol       Date:  2022-07-23       Impact factor: 5.363

2.  Trajectories of Antidepressant Medication before and after the Onset of Unemployment by Subsequent Employment Experience.

Authors:  Taina Leinonen; Netta Mäki; Pekka Martikainen
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

3.  Changes in prescription of antidepressants and disability pension due to back pain, compared with other musculoskeletal and other somatic diagnoses: a cohort study in Sweden.

Authors:  Annina Ropponen; Syed Ghulam Rahman; Pia Svedberg; Magnus Helgesson; Thomas Ernst Dorner; Ellenor Mittendorfer-Rutz
Journal:  BMJ Open       Date:  2019-09-17       Impact factor: 2.692

4.  Use of sequence analysis for classifying individual antidepressant trajectories to monitor population mental health.

Authors:  Mark Cherrie; Sarah Curtis; Gergő Baranyi; Stuart McTaggart; Niall Cunningham; Kirsty Licence; Chris Dibben; Clare Bambra; Jamie Pearce
Journal:  BMC Psychiatry       Date:  2020-11-23       Impact factor: 3.630

5.  Unemployment Trajectories and the Early Risk of Disability Pension among Young People with and without Autism Spectrum Disorder: A Nationwide Study in Sweden.

Authors:  Tea Lallukka; Ellenor Mittendorfer-Rutz; Jenni Ervasti; Kristina Alexanderson; Marianna Virtanen
Journal:  Int J Environ Res Public Health       Date:  2020-04-05       Impact factor: 3.390

6.  Technology-induced job loss risk, disability and all-cause mortality in Norway.

Authors:  Bernt Bratsberg; Ole Rogeberg; Vegard Skirbekk
Journal:  Occup Environ Med       Date:  2021-09-24       Impact factor: 4.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.